Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
4SC AG
4SC presents Phase I data on its histone deacetylase HDAC inhibitor 4SC-201 at ASCO
June 12th, 2009
4SC AG (Frankfurt, Prime Standard: VSC) the German drug discovery and development company, in conjunction with Royal Marsden Hospital in Sutton, England, announced that it will present Phase I data on 4SC-201, an innovative histone deacetylase (HDAC) inhibitor, at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, USA, from May 29 to June 2, 2009. The Phase I data, generated in advanced solid tumors will form the basis of 4SC's drug development program in oncology. In the Phase I trial, 4SC 201 was orally administered to 18 patients and was applied in therapy cycles, consisting of a once daily oral dose over five consecutive...
Source: Health Business Week (2009-06-12)
|
